Coherus BioSciences Inc. (CHRS)
0.78
-0.04 (-4.49%)
At close: Apr 04, 2025, 3:59 PM
0.77
-1.29%
After-hours: Apr 04, 2025, 05:37 PM EDT
Coherus BioSciences Inc. Revenue Breakdown
| Quarter | Sep 30, 2024 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
|---|---|---|---|---|
| Product and Service, Other Revenue | 220K | 82.5M | 87.6M | 83M |
| Product and Service, Other Revenue Growth | -99.73% | -5.82% | +5.54% | n/a |
| Product Revenue | 70.55M | n/a | n/a | n/a |
| Product Revenue Growth | n/a | n/a | n/a | n/a |
Revenue by Geography
| Quarter | Dec 31, 2019 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 |
|---|---|---|---|---|
| Non Us Revenue | n/a | 1.56M | 1.81M | 2.24M |
| Non Us Revenue Growth | -100.00% | -14.22% | -18.98% | n/a |
| United States Revenue | 356.07M | n/a | 188.29M | n/a |
| United States Revenue Growth | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 34.74M | 35.16M | 49.73M | 48.95M | 48.22M | 45.14M | 49.15M | 53.62M | 44.83M | 51.28M | 48.75M | 50.05M | 39.92M | 40.34M | 39.39M | 37.69M | 31.98M | 34.05M | 35.35M | 36.07M | 31.83M | 36.46M | 32.68M | 33.84M | 25.37M | 18.39M | 16.58M | 14.98M | 13.99M | 23.53M | 18.8M | 15.29M | 13.64M | 11.26M | 11.4M | 10.97M | 10.17M | 8.82M | 6.09M |
| Selling, General, and Administrative Revenue Growth | -1.20% | -29.29% | +1.60% | +1.50% | +6.82% | -8.16% | -8.33% | +19.61% | -12.57% | +5.18% | -2.60% | +25.37% | -1.04% | +2.42% | +4.50% | +17.85% | -6.07% | -3.67% | -2.00% | +13.33% | -12.69% | +11.54% | -3.42% | +33.39% | +37.94% | +10.94% | +10.68% | +7.07% | -40.56% | +25.16% | +22.94% | +12.09% | +21.18% | -1.21% | +3.88% | +7.93% | +15.30% | +44.75% | n/a |
| Research and Development Revenue | 21.68M | 20.77M | 26.96M | 25.3M | 25.65M | 23.27M | 34.15M | 29.02M | 45.81M | 41.61M | 82.92M | 50.76M | 54.09M | 54.77M | 203.49M | 44.63M | 38.85M | 26.17M | 33.11M | 34.95M | 21.57M | 18.88M | 18.79M | 26.66M | 31.6M | 26.52M | 25.45M | 31.49M | 42.63M | 34.5M | 53.77M | 59.01M | 64.57M | 65.54M | 65.31M | 51.43M | 68.22M | 56.94M | 36.47M |
| Research and Development Revenue Growth | +4.37% | -22.98% | +6.55% | -1.33% | +10.23% | -31.88% | +17.68% | -36.64% | +10.09% | -49.82% | +63.34% | -6.14% | -1.24% | -73.09% | +355.97% | +14.87% | +48.44% | -20.94% | -5.27% | +62.04% | +14.22% | +0.50% | -29.53% | -15.63% | +19.17% | +4.18% | -19.16% | -26.13% | +23.55% | -35.84% | -8.87% | -8.62% | -1.48% | +0.35% | +26.99% | -24.60% | +19.80% | +56.15% | n/a |